

DELTA CURE 5TH INTERNATIONAL MEETING
Milano, 15-16 ottobre 2026 – Fondazione Cariplo Conference
Centre
Chairs: Pietro Lampertico, Heiner Wedemeyer
ID 150-488154

DESTINATARI

Professione	Discipline
MEDICO CHIRURGO	ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; EMATOLOGIA; GASTROENTEROLOGIA; MALATTIE INFETTIVE; MEDICINA INTERNA; MICROBIOLOGIA E VIROLOGIA; PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO- CLINICHE E MICROBIOLOGIA); IGIENE, EPIDEMIOLOGIA E SANITÀ PUBBLICA; DIREZIONE MEDICA DI PRESIDIO OSPEDALIERO; EPIDEMIOLOGIA;

INFORMAZIONI GENERALI

Crediti Formativi: Sono stati assegnati all'evento n. 14 Crediti formativi, secondo il programma per l'Educazione Continua in Medicina (ID. evento N. 150-488154). L'assegnazione dei crediti formativi è subordinata alla presenza al 90% dei lavori e alla corretta compilazione di almeno il 75% delle domande proposte all'interno del questionario di valutazione finale. Saranno inoltre obbligatorie la rilevazione della presenza e la compilazione del questionario di gradimento dell'evento formativo.

Sede dell'evento: Fondazione Cariplo Conference Centre – Via Romagnosi 8 – 20121 Milano

Provider e Segreteria Scientifica
Effetti Srl - Via G.B. Giorgini, 16 – 20151 Milano

RAZIONALE

Recognized as the leading international forum fully dedicated to **Hepatitis Delta Virus**, Delta Cure continues to bring together leading experts, clinicians, and researchers from around the world.

effetti srl
via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.
società conforme
al D.Lgs. 231/2001

Since its beginning, this meeting has played a central role in advancing the collective understanding of this uniquely severe and challenging form of viral hepatitis. The 2026 **scientific program** will again offer a comprehensive exploration of the **virus, epidemiology, virology, immunology, clinical progression**, and effect of therapy on long-term complications. For the first time, **all the abstracts accepted** for the Delta Cure 2026 meeting **will be PUBLISHED** in a **dedicated supplement of the indexed journal BMJ Open Gastroenterology**, further enhancing the visibility and impact of the scientific contributions presented at the meeting. We remain dedicated to supporting the **next generation of HBV/HDV** researchers: a significant portion of the program will be reserved for **ORAL ABSTRACT PRESENTATIONS** by early-career investigators, fostering their integration into the international research community.

PROGRAMMA

Day 1 - October 15th

- 11.00-11.15** **Welcome by the Chairs**
P. Lampertico and H. Wedemeyer
- SESSION 1** **Bookmarks and Epidemiology**
- 11.15-11.30** **Bookmarks in HDV: a 2025/2026 overview**
- 11.30-11.45** **Epidemiology of HDV in Low to Middle IC: WHO perspectives**
- 11.45-12.00** **Epidemiology of HDV in US: still a black box?**
- 12.00-12.10** **Oral presentation 1 (selected abstract)**
- 12.10-12.45** **Panel discussion**
- 12.45-13.45** **Lunch**
- SESSION 2** **Pathophysiology: Virology and Immunology**
- 13.45-14.00** **Virology update**
- 14.00-14.15** **Immunology update: lessons learned from liver spatial transcriptomics**
- 14.15-14.25** **Oral presentation 2 (selected abstract)**
- 14.25-14.35** **Oral presentation 3 (selected abstract)**
- 14.35-14.50** **Poster summaries 1**
- 14.50-15.20** **Panel discussion**
- 15.20-16.20** **Coffee break and Poster Session No. 1 with guided Poster Tour**
- SESSION 3** **Diagnostics and Natural History**
- 16.20-16.35** **Diagnostics update**

effetti srl
via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

16.35-16.50	HCC in HDV patients: pathogenesis, incidence and predictors
16.50-17.00	Oral presentation 4 (selected abstract)
17.00-17.10	Oral presentation 5 (selected abstract)
17.10-17.25	Poster summaries 2
17.25-17.55	Panel discussion
17.55-18.55	Presentation of Delta Cure 2026 Awardee Distinguished Lecture
18.55-19.00	Day 1 closing <i>P. Lampertico and H. Wedemeyer</i>
20.00 -22.00	Networking Dinner

Day 2 - October 16th

SESSION 4	Current treatment options
08.30-08.45	BLV in clinical trials: filling the gaps (a debate)
08.45-09.00	Long-term outcomes in BLV-treated patients
09.00-09.10	Oral presentation 6 (selected abstract)
09.10-09.20	Oral presentation 7 (selected abstract)
09.20-09.30	Oral presentation 8 (selected abstract)
09.30-09.45	Poster summaries 3
09.45-10.15	Panel discussion
10.15-11.15	Coffee break and Poster Session No. 2 with guided Poster Tour
SESSION 5	Treatment options in clinical development
11.15-11.30	Anti-HBs monotherapies: results of phase II/III studies
11.30-11.45	Anti-HBs and siRNA combination: results of phase II/III studies
11.45-12.00	Other therapeutic approaches for HDV in phase I /II/III
12.00-12.10	Oral presentation 9 (selected abstract)
12.10-12.20	Oral presentation 10 (selected abstract)
12.20-12.35	ASO-based phase III studies in HBV: any relevance for HDV?
12.35-13.05	Panel Discussion
13.05-14.00	Lunch
SESSION 6	Unmet needs in Hepatitis Delta
14.00-14.15	BAVENO VIII update: any change for HDV patients?
14.15 -14.30	Liver transplantation for HDV: time for HBIG-free regimens?
14.30-14.45	The impact of MASLD in HBV and HDV: methHBV and methHDV?
14.45-15.15	Panel discussion

effetti srl
 via G.B. Giorgini 16
 20151 Milano, I
 tel: +39 02 3343281
 effetti@effetti.it
 effetti@pec.effetti.it
 www.effetti.it
 www.makevent.it
 p. IVA: 10756900154
 cuu: USAL8PV
 cap. soc.: € 100.000,00 i.v.
 società conforme
 al D.Lgs. 231/2001

15.15-15.50 Roundtable discussion

Academia, Pharma, Diagnostics, Patient Associations

15.50-16.00 Closing Remarks and farewell

P. Lampertico and H. Wedemeyer

ACRONIMI

BMJ: British Medical Journal

HBV: Hepatitis B Virus

HDV: Hepatitis D Virus

IC: Income Country

WHO: World Health Organization

US: United States

HCC: Hepatocellular Carcinoma

BLV: Bulevirtide

Anti-HBs: Hepatitis B surface antibodies

siRNA: small interfering RNA

ASO: Antisense Oligonucleotide

HBIG: Hepatitis B Immune Globulin

MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease

metHBV: Method for Hepatitis B Virus

metHDV: Method for Hepatitis D Virus

effetti srl

via G.B. Giorgini 16

20151 Milano, I

tel: +39 02 3343281

effetti@effetti.it

effetti@pec.effetti.it

www.effetti.it

www.makevent.it

p. IVA: 10756900154

cuu: USAL8PV

cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001


Milano, 25 maggio 2026

La sottoscritta IDA TACCONI, nata a Milano l'11/09/1958, residente a Corsico (MI), codice fiscale TCCDIA58P51F205R, telefono 02.3343281, email ida.tacconi@effetti.it, in qualità di legale rappresentante del Provider accreditante Effetti, con sede legale in via G.B. Giorgini 16, Milano DICHIARA CHE

i curriculum vitae sono consultabili sul sito del Provider Effetti

www.makevent.it

In fede,



effetti srl

via G.B. Giorgini 16
20151 Milano, I
tel: +39 02 3343281
effetti@effetti.it
effetti@pec.effetti.it
www.effetti.it
www.makevent.it
p. IVA: 10756900154
cuu: USAL8PV
cap. soc.: € 100.000,00 i.v.

società conforme
al D.Lgs. 231/2001

IMQ SGQ CERTIFICAZIONE
UNI EN ISO 9001:2015

